Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019-2020 Influenza Season.

Imran, Mahrukh; Puig-Barbera, Joan; Ortiz, Justin R; Fischer, Lauren; O'Brien, Dan; Bonafede, Machaon; Mansi, James A; Boikos, Constantina

Imran, Mahrukh; Puig-Barbera, Joan; Ortiz, Justin R; Fischer, Lauren; O'Brien, Dan; Bonafede, Machaon; Mansi, James A; Boikos, Constantina.

Afiliación

Imran M; Seqirus Inc., Kirkland, Quebec, Canada.
Puig-Barbera J; Foundation for the Promotion of Health and Biomedical Research, Valencia, Spain.
Ortiz JR; University of Maryland School of Medicine, Baltimore, Maryland, USA.
Fischer L; Veradigm, Chicago, Illinois, USA.
O'Brien D; Veradigm, Chicago, Illinois, USA.
Bonafede M; Veradigm, Chicago, Illinois, USA.
Mansi JA; Seqirus Inc., Kirkland, Quebec, Canada.
Boikos C; Seqirus Inc., Kirkland, Quebec, Canada.

Open Forum Infect Dis ; 9(5): ofac167, 2022 May.

Article en En | MEDLINE | ID: mdl-35493131

Palabras clave

adjuvanted influenza vaccine; high-dose influenza vaccine; older adults; quadrivalent inactivated influenza vaccine; relative vaccine effectiveness

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: Open Forum Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google